Skip to main content
. 2019 Oct 1;30(12):2449–2463. doi: 10.1681/ASN.2019040331

Figure 5.

Figure 5.

Discontinuation of prophylactic eculizumab therapy. Courses of prophylactic eculizumab therapies, according to the risk stratification and genetic background. Ecu, eculizumab; HR, high-risk; MR, moderate risk; MV, multiple complement variants; NV, no genetic variants.